Skip to main
CELU
CELU logo

Celularity (CELU) Stock Forecast & Price Target

Celularity (CELU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celularity Inc is positioned favorably due to its innovative offerings in placental-derived cell therapies, with significant promise demonstrated through clinical efficacy in wound healing, particularly with its product PDA-002, which showed superior ulcer closure rates compared to FDA-approved products. The company's bio-banking segment, which contributes the majority of its revenue, underlines a strong business foundation that supports its research and development activities across other therapeutic areas like cancer and immunologic diseases. Additionally, the successful demonstration of improved structural integrity and handleability in soft tissue repair reinforces Celularity's potential competitiveness in the biotechnology sector, providing a compelling outlook for investors.

Bears say

Celularity Inc faces significant operational risks that may adversely impact its clinical trials, particularly due to potential manufacturing failures, which could hinder both its bio-banking and degenerative diseases sectors. Additionally, the effectiveness of its NK cell therapies is compromised by a natural decline in NK cell function with age, leading to decreased efficacy in older populations, which represents a critical target demographic for its treatments. These fundamental challenges in maintaining operational integrity and addressing efficacy in an aging patient base contribute to a negative outlook for the company's stock.

Celularity (CELU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celularity (CELU) Forecast

Analysts have given Celularity (CELU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Celularity (CELU) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celularity (CELU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.